Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: S-1 Clear all
Completed Phase 1 Interventional

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

NCT00400023
View directory record Official record
Conditions
Tumors
Interventions
S-1, FT
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 16, 2026, 6:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617
View directory record Official record
Conditions
Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation
Radiation · Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
14
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 16, 2026, 6:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

NCT03787602
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
KRT-232, Avelumab
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Phase 2 Interventional

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166
View directory record Official record
Conditions
Medulloblastoma
Interventions
Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 59 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
10
States / cities
Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
KRT-232, acalabrutinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 16, 2026, 6:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain Sensitivity During Puberty

NCT05145595
View directory record Official record
Conditions
Pain
Interventions
Thermal Sensory Analyzer, Pressure Stimuli, Mechanical Stimuli, Pain Ratings, Thermal pain thresholds, Pressure pain thresholds (PPT), Mechanical temporal summation, Conditioned pain modulation (CPM) efficiency, Offset analgesia efficiency, Cold pain tolerance
Device · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
9 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Enrolling by invitation No phase listed Observational

The ION Facet Screw System Ambispective Evaluation

NCT06720948
View directory record Official record
Conditions
Intra-facet ION 3D Facet Screw System
Interventions
ION 3D Facet Screw System
Device
Lead sponsor
SurGenTec LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fort Wayne, Indiana • Oklahoma City, Oklahoma • San Angelo, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Not applicable Interventional

Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury

NCT07504055
View directory record Official record
Conditions
Spinal Cord Injury, Orthostatic Hypertension, Autonomic Dysreflexia
Interventions
Spinal Cord Transcutaneous Stimulation
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Completed No phase listed Observational

Radiofrequency Nerve Ablation Versus Sham to Treat Chronic Low Back Pain Caused by Sacroiliac Joint Dysfunction

NCT01104051
View directory record Official record
Conditions
Sacroiliac Joint Dysfunction
Interventions
Not listed
Lead sponsor
Coastal Orthopedics & Sports Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 16, 2026, 6:27 AM EDT
Suspended Not applicable Interventional

Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis

NCT06496867
View directory record Official record
Conditions
Multiple Closed Pelvic Fractures With Disruption of Pelvic Ring, Fragility Fracture, Internal Fixation, Nonoperative Care
Interventions
Early Internal Fixation, Nonoperative Care with Early Rehabilitation
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Terminated Phase 3 Interventional

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

NCT00602745
View directory record Official record
Conditions
Pancreatic Neoplasm, Neoplasm Metastasis
Interventions
S-1, 5-Fluorouracil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Completed Phase 3 Interventional

Titanium Surgical Mesh and MOSS-Miami Screws for Lumbar Fusion.

NCT00215319
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Lumbar I/F with cage and pedicle screws
Device
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years to 79 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Dothan, Alabama • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 16, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Interventions
KRT-232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 16, 2026, 6:27 AM EDT
Terminated Phase 1 Interventional Results available

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730
View directory record Official record
Conditions
Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Echocardiography, Lenalidomide, Navtemadlin
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers

NCT04700163
View directory record Official record
Conditions
Covid19
Interventions
C144-LS and C-135-LS
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 16, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-004, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 16, 2026, 6:27 AM EDT
Not listed No phase listed Observational

Clinical and Radiographic Outcomes of TLIF w/3D Printed Cellular Implant

NCT05023733
View directory record Official record
Conditions
Foraminal Stenosis, Degenerative Disc Disease, Lumbar Spondylolisthesis, Lumbar Spinal Stenosis
Interventions
CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®
Device
Lead sponsor
Farhan Karim
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 16, 2026, 6:27 AM EDT
Active, not recruiting Phase 1 Interventional

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

NCT03041688
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Navtemadlin, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 16, 2026, 6:27 AM EDT
Not listed Phase 1Phase 2 Interventional

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
TL-895, KRT-232
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Not applicable Interventional

Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)

NCT05731986
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Diseases, Trauma, Nervous System, Nervous System Diseases, Central Nervous System Diseases, Hypotension, Orthostatic Hypotension, Cardiovascular Diseases, Acute Spinal Cord Injury, Blood Pressure
Interventions
Orthostatic challenge, Biostim-5 transcutaneous spinal stimulation - Mapping, Biostim-5 transcutaneous spinal stimulation - "Optimal" testing, Biostim-5 transcutaneous spinal stimulation - "Sham" testing
Diagnostic Test · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 16, 2026, 6:27 AM EDT
Terminated Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions
KRT-232, Cytarabine, Decitabine
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 16, 2026, 6:27 AM EDT
Terminated Not applicable Interventional Results available

Low Level Laser Therapy With Physical Therapy for Chronic Musculoskeletal Pain

NCT02785432
View directory record Official record
Conditions
Chronic Pain
Interventions
Sham low level laser, Active low level laser
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 16, 2026, 6:27 AM EDT
Recruiting Phase 3 Interventional

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 16, 2026, 6:27 AM EDT